Ardelyx Inc (ARDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ardelyx Inc (ARDX) has a cash flow conversion efficiency ratio of -0.217x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.24 Million) by net assets ($148.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Ardelyx Inc to measure how many days the company can operate on defensive assets alone.
Ardelyx Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ardelyx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ardelyx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ardelyx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Gehua CATV Network Co Ltd
SHG:600037
|
-0.006x |
|
Companhiade Eletricidade do Estado da Bahia - COELBA
SA:CEEB3
|
0.049x |
|
SLC Agrícola S.A
SA:SLCE3
|
0.152x |
|
Guangzhou Hexin Instrument Co Ltd
SHG:688622
|
N/A |
|
Rackspace Technology Inc
NASDAQ:RXT
|
-0.004x |
|
Direcional Engenharia S.A.
SA:DIRR3
|
0.055x |
|
Olaplex Holdings Inc
NASDAQ:OLPX
|
0.009x |
|
Shinkong Synthetic Fiber Corp
TW:1409
|
-0.061x |
Annual Cash Flow Conversion Efficiency for Ardelyx Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ardelyx Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Ardelyx Inc (ARDX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $166.95 Million | $-42.48 Million | -0.254x | +1.59% |
| 2024-12-31 | $173.29 Million | $-44.81 Million | -0.259x | +51.92% |
| 2023-12-31 | $166.82 Million | $-89.72 Million | -0.538x | +24.50% |
| 2022-12-31 | $98.33 Million | $-70.04 Million | -0.712x | +61.42% |
| 2021-12-31 | $82.62 Million | $-152.55 Million | -1.846x | -185.95% |
| 2020-12-31 | $126.11 Million | $-81.44 Million | -0.646x | -57.59% |
| 2019-12-31 | $186.66 Million | $-76.48 Million | -0.410x | +32.47% |
| 2018-12-31 | $115.81 Million | $-70.27 Million | -0.607x | -29.67% |
| 2017-12-31 | $139.31 Million | $-65.19 Million | -0.468x | +2.32% |
| 2016-12-31 | $193.15 Million | $-92.53 Million | -0.479x | +27.38% |
| 2015-12-31 | $108.90 Million | $-71.84 Million | -0.660x | -398.80% |
| 2014-12-31 | $60.68 Million | $13.40 Million | 0.221x | +189.28% |
| 2013-12-31 | $-7.32 Million | $1.81 Million | -0.247x | +98.61% |
| 2012-12-31 | $-1.24 Million | $21.98 Million | -17.769x | -- |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more